HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHTtm ? now ...

With the launch of FibroSIGHT, HistoIndex reaffirms its long-standing commitment in advancing fibrosis assessment and personalized treatment for MASH. By bridging research with clinical care ...

Gilead's top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis ... selonsertib in patients with bridging fibrosis due to NASH and the ...

However, there are limited prospective data in well-characterised patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) with bridging fibrosis and cirrhosis regarding the optimal ...

These injuries can progress from the initial stage of fatty liver accumulation (hepatic steatosis) to more severe conditions, including inflammation and fat accumulation (steatohepatitis), liver ...

DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight ... hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of Metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by steatosis and inflammation, which can ...

Continued hepatic assaults, including dietary, alcoholic, viral, and medicinal, can facilitate the transition of steatohepatitis to liver fibrosis. Liver fibrosis has five categories: minimal ...